AFT signs North American licensing deal for Pascomer topical treatment

AFT signs North American licensing deal for Pascomer topical treatment
Paul McBeth
By Paul McBeth July 5 (BusinessDesk) - AFT Pharmaceuticals is eyeing a US$10 million payment from a North America licensing deal but is keeping its earnings guidance unchanged for now.  The maker of Maxigesic painkillers reached the licensing and development agreement with US-based Timber Pharmaceuticals for its Pascomer drug, which treats skin lesions known as facial angiofibromas associated with the genetic disorder, tuberous sclerosis.  Timber will cover the cost of two clinical trials involving 120 patients, with the results due ne...

More Services

Former school lunch provider in liquidation
Law & Regulation

Former school lunch provider in liquidation

Secret Chef stopped trading in December last year.

Michael Neilson 18 Mar 2025
Libelle approached liquidators late last week
Services Exclusive

Libelle approached liquidators late last week

Liquidators were called on the same day a student was burned by a meal.

Cécile Meier 11 Mar 2025
HelloFresh faces legal action for misleading consumers
Services

HelloFresh faces legal action for misleading consumers

Previous customers were allegedly offered a discount voucher.

BD AI 11 Mar 2025
NZ Post increasing Manila outsourcing
Services

NZ Post increasing Manila outsourcing

The Philippines call centre is set to expand by 15 people in May.

John Anthony 06 Mar 2025